All Valneva SE articles
-
NewsValneva reports high sustained immune response in adolescents one year after Chikungunya Vaccine
Valneva SE, a specialty vaccine company, has reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, which showed a sustained 98.3% sero-response rate one-year after single vaccination.
-
NewsValneva announces new IXIARO® supply contract with the US government
Specialty vaccine company Valneva SE has announced the signing of a new $32 million contract with the United States Department of Defense for the supply of its Japanese encephalitis vaccine, IXIARO®.